Key result
Tirofiban during mechanical thrombectomy linked to ~5-fold higher extracranial bleeding with no difference in ICH.
Why the study?
Many patients fail to achieve functional independence after mechanical thrombectomy despite recanalisation, potentially due to incomplete microvascular reperfusion that periprocedural tirofiban might improve.
Does periprocedural tirofiban improve recanalisation or increase bleeding in patients undergoing mechanical thrombectomy for large vessel occlusion?
Cohort (n=186)
No
Does periprocedural tirofiban improve recanalisation or increase bleeding in patients undergoing mechanical thrombectomy for large vessel occlusion?
Periprocedural tirofiban during mechanical thrombectomy for large vessel occlusion was associated with increased extracranial bleeding and radiological mass effect without improving recanalisation success or mortality.
Answers are grounded in this paper and cite their sources.
Should not yet change practice for tirofiban in acute stroke; leaves open net benefit pending randomized trials.
Background and aims Approximately one third of patients with large vessel occlusion fail to achieve functional independence despite successful recanalisation following mechanical thrombectomy (MT), theorised to be secondary to incomplete restoration of microvascular perfusion. Periprocedural antiplatelet therapy may improve microvascular reperfusion. Tirofiban, a glycoprotein IIb/IIIa inhibitor commonly used in acute coronary syndrome, is occasionally used off-license during MT. This study compares outcomes following MT with and without periprocedural tirofiban at North Bristol NHS Trust (NBT). Methods A retrospective cohort study was conducted including patients who underwent MT at NBT between January and July 2025. Clinical records were reviewed to assess intracranial haemorrhage, mortality, recanalisation success, neurological outcomes, and stent re-occlusion. Results 186 patients were included (mean age 69.8 years), 20 received tirofiban. Intracranial haemorrhage occurred in 25.8% overall, with no significant difference between tirofiban (30%) and non-tirofiban groups (25.3%). Bleeding from other sources (15.0% tiro vs 3.0% non-tiro, p=0.013) and mass effect (15.0% tiro vs 3.6% non-tiro, p=0.025) were more frequent with tirofiban. Malignant MCA syndrome occurred only in non-tirofiban patients (3.8%). Successful recanalisation (TICI 2b–3) was achieved in 87.1%, with no difference in TICI outcomes (p=0.32). Three and 6-month mortality was comparable between groups. Conclusions Periprocedural tirofiban was not associated with increased intracranial haemorrhage, mortality, or recanalisation success but was associated with higher rates of extracranial bleeding and radiological mass effect Conflict of interest Hannah Timperley: nothing to disclose
No takes yet. Share an insight, caveat, or question.
Timperley et al. (2026) conducted a cohort in Large vessel occlusion undergoing mechanical thrombectomy (n=186). Periprocedural tirofiban vs. No tirofiban was evaluated on Intracranial haemorrhage. Periprocedural tirofiban during mechanical thrombectomy did not affect intracranial haemorrhage but was associated with higher rates of extracranial bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: